Document Detail


CD14CD16 monocyte subset levels in heart failure patients.
MedLine Citation:
PMID:  20364047     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Our aim was to define the distribution of monocyte subsets in a cohort of congestive heart failure (CHF) patients, to verify whether increased severity of CHF is linked to the expansion of specific monocyte subsets, and finally to investigate the relationship between monocyte subset relative frequencies, laboratory parameters of inflammation, and monocyte ACE expression. Thirty consecutive CHF patients and 26 healthy control subjects were evaluated for peripheral blood monocyte expression of CD14, CD16 and CD143 (ACE) by flow-cytometry, and for endothelial-derived soluble CD146 levels by ELISA. CD14++ CD16+ frequency was significantly higher in CHF patients than in Controls (%, median value and IQ) (12.3, 8.7-14.8 vs 5.9, 4.7-6.9, p< 0.05, CHF vs Controls), and it increased depending on how high NYHA class was, on worsening LV ejection fraction and on circulating pro-BNP values. Furthermore, it was associated with increasing creatinine and with decreasing GFR and albumin levels. Monocyte CD143 expression was significantly elevated in CHF patients as compared to Controls, and positively associated with CD14++ CD16+ levels. Frequencies of CD14+ CD16+ monocytes were significantly lower in CHF patients as compared to Controls, and negatively correlated with levels of soluble CD146 (r=-0.529; p 0.048). In conclusion, monocytic CD14++ CD16+ frequency and CD143 levels are increased and reflect disease status and progressive cardiac deterioration in CHF patients. The CD14+ CD16+ subset is depleted in CHF and is linked to endothelial damage in this group of patients. Although the question of whether differences in monocyte CD14CD16 expansion are causal or whether they represent a marker of HF progression which is potentially relevant for risk prediction remains unanswered, we believe that our data represent an important tool for exploring the role of selective inflammatory pathways in CHF progression.
Authors:
Chiara Barisione; Silvano Garibaldi; Giorgio Ghigliotti; Patrizia Fabbi; Paola Altieri; Maria Carla Casale; Paolo Spallarossa; Giovanni Bertero; Manrico Balbi; Luca Corsiglia; Claudio Brunelli
Related Documents :
16713737 - Long-term effects of levosimendan infusion on inflammatory processes and sfas in patien...
3163697 - The expression of autoimmune polyglandular disease type i appears associated with sever...
16887387 - Clinical trials update from the european society of cardiology heart failure meeting: t...
19041537 - Identification of congestive heart failure via respiratory variation of inferior vena c...
9009687 - Testicular feminization syndrome diagnosed in an elderly patient at surgery. a case rep...
1527547 - Improvement of parkinsonian features correlate with high plasma levodopa values after b...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Disease markers     Volume:  28     ISSN:  1875-8630     ISO Abbreviation:  Dis. Markers     Publication Date:  2010  
Date Detail:
Created Date:  2010-04-05     Completed Date:  2010-06-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8604127     Medline TA:  Dis Markers     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  115-24     Citation Subset:  IM    
Affiliation:
Division of Cardiology, Department of Internal Medicine, Research Center of Cardiovascular Biology, University of Genova, V.le Benedetto XV, 6 16132 Genova, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antigens, CD14 / blood*
Biological Markers / blood
C-Reactive Protein / metabolism
Case-Control Studies
Cohort Studies
Disease Progression
Heart Failure / blood*,  physiopathology
Humans
Inflammation Mediators / blood
Kidney / physiopathology
Leukocyte Count
Male
Monocytes / classification*,  enzymology,  immunology*
Neutrophils
Peptidyl-Dipeptidase A / blood
Receptors, IgG / blood*
Chemical
Reg. No./Substance:
0/Antigens, CD14; 0/Biological Markers; 0/FCGR3B protein, human; 0/Inflammation Mediators; 0/Receptors, IgG; 9007-41-4/C-Reactive Protein; EC 3.4.15.1/Peptidyl-Dipeptidase A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Coincidence of moderately elevated N-terminal pro-B-type natriuretic peptide, endothelial progenitor...
Next Document:  WORK: A historical evaluation of the impact and evolution of its editorial board.